Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

175

Participants

Timeline

Start Date

July 6, 2022

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Becker Muscular Dystrophy
Interventions
DRUG

Sevasemten 10 mg

Sevasemten is administered orally once per day

DRUG

Sevasemten 5 mg

Sevasemten is administered orally once per day

DRUG

Sevasemten 12.5 mg

Sevasemten is administered orally once per day

DRUG

Placebo

Placebo is administered orally once per day

Trial Locations (51)

1010

Optimal Clinical Trials, Auckland

4000

Centre Hospitalier Régional de la Citadelle, Liège

9000

University Hospital Gent, Ghent

13005

Centre de Reference des Maladies Neuromusculaires et de la SLA - AP-HM Hopital de La Timone, Marseille

14642

University of Rochester Medical Center, Rochester

15224

University of Pittsburgh, Pittsburgh

19104

University of Pennsylvania, Philadelphia

20014

Hospital Universitario Donostia, Donostia / San Sebastian

20122

Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico di Milano, Milan

21205

Kennedy Krieger Institute, Baltimore

23298

Virginia Commonwealth University Health, Richmond

27278

Rare Disease Research, LLC NC, Hillsborough

30329

Rare Disease Research, Atlanta

32611

University of Florida, Gainesville

35128

Azienda Ospedale - Università Padova, Padua

43205

Nationwide Children's Hospital, Columbus

44093

CHU de Nantes, Nantes

45219

University of Cincinnati Gardner Neuroscience Institute, Cincinnati

46026

Hospital Universitari i Politecnic La Fe, Valencia

46202

Indiana University School of Medicine, Indianapolis

49202

Schneider Children's Hospital of Israel, Petah Tikva

52242

University of Iowa, Iowa City

55455

University of Minnesota, Minneapolis

60611

Northwestern University, Chicago

63110

Washington University School of Medicine, St Louis

66160

University of Kansas Medical Center, Kansas City

72202

Arkansas Children's Hospital, Little Rock

75013

AP-HP Hopital Pitie-Salpetriere, Paris

76208

Neurology Rare Disease Center, Denton

78759

National Neuromuscular Research Institute, Austin

80045

UC Denver, Aurora

80336

Klinikum der Ludwig-Maximilians-Universitaet Muenchen, Munich

90095

UCLA Medical Center, Los Angeles

91240

Hadassah University Hospital, Jerusalem

92037

UC San Diego, La Jolla

92868

UC Irvine Medical Center, Orange

94304

Stanford Neuroscience Health Center, Palo Alto

95817

UC Davis Medical Center, Sacramento

01605

University of Massachusetts Memorial Medical Center, Worcester

VIC, 3065

St Vincent's Hospital Melbourne, Fitzroy

Unknown

Universitaire Ziekenhuizen Leuven, Leuven

Rigshospitalet, Copenhagen

06001

CHU de Nice - Hopital Pasteur 2 - Centre de reference des Maladies Neuromusculaires, Nice

00168

Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore, Rome

2333 ZA

Leids Universitair Medisch Centrum, Leiden

08035

Hospital Universitario Vall d'Hebron, Barcelona

08907

Hospital Universitari de Bellvitge, Barcelona

NW1 2PG

University College London Hospital, London

SW17 0QT

St. George's University Hospitals NHS Foundation Trust, London

NE7 7DN

Newcastle Freeman Hospital, Newcastle

M68HD

Salford Royal Hospital, Salford

Sponsors
All Listed Sponsors
collaborator

Medpace, Inc.

INDUSTRY

collaborator

ImagingNMD

UNKNOWN

collaborator

SYSNAV

INDUSTRY

lead

Edgewise Therapeutics, Inc.

INDUSTRY